Performance over 1-Year: 20.9% Expense Ratio: 0.50% Annual Dividend Yield: 0.04% 3-Month Average Daily Volume: 66,070 Assets Under Management: $188.3 million Inception Date: December 30, 2014 Issuing Company: ALPS
SBIO is a fund focused on the U.S. health and biotechnology sector, targeting companies with drugs in Phase II or Phase III clinical trials. This fund invests in firms with market caps of $200 million to $5 billion, so it contains micro-cap and mid-cap companies, as well as small-cap, in its portfolio.6? The fund's top three holdings include Immunomedics Inc. (IMMU), a pharmaceuticals company focused on cancer treatments; United Therapeutics Corp. (UTHR), a biotechnology company; and Acceleron Pharma Inc. (XLRN), a biopharmaceutical company
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.